论文部分内容阅读
目的 :评价靶向性新药盐酸米托蒽醌毫微球对原发性肝癌的治疗效果。方法 :将 2 0例原发性肝癌随机分为试验组与对照组。试验组使用盐酸 2 3 .52mg/m2 静脉滴注 ,对照组为盐酸米托蒽醌 1 2mg/m2 静脉滴注 ,两组均为 2 1天重复给药 ,共用两次。结果 :治疗前后CT扫描评价近期疗效 ,试验组CR0例 ,PR0例 ,SD7例 ,PD3例 ;对照CR0例 ,PR0例 ,SD4例 ,PD6例 ,两组有效率均为 0 %。中位生存期试验组 6 .5月 ,对照组 2 .0月 ,差异有显著性意义 (P <0 .0 5)。试验组用药后 2例KPS评分增加 ,对照组无 1例增加。两组急性毒性反应较轻 ,患者可以耐受。结论 :米托蒽醌毫微球静脉滴注对原发性肝癌的近期疗效与米托蒽醌相似 ,但前者有明显延长患者生存时间的作用 ,急性毒性反应可接受
Objective: To evaluate the therapeutic effect of targeted drug mitoxantrone nanospheres on primary liver cancer. Methods: 20 cases of primary liver cancer were randomly divided into experimental group and control group. The experimental group was treated with intravenous infusion of hydrochloric acid at 23.52mg / m2, and the control group was treated with mitoxantrone 12mg / m2 intravenously. The two groups were given 21 repeated administrations twice daily. Results: The CT scan before and after treatment evaluated the short-term curative effect. CR0, PR0, SD7 and PD3 in the experimental group; CR0, PR0, SD4 and PD6 in both groups. The median survival time of test group 6.5 months, control group 2.0 months, the difference was significant (P <0.05). The KPS scores of two cases increased in the experimental group and none in the control group increased. Two groups of acute toxicity less patients can tolerate. Conclusion: Mitoxantrone nanoelectrospray intravenous drip on the efficacy of mitomycin-treated patients with mitochondria is similar to that of mitoxantrone, but the former has the effect of significantly prolonging the survival time of patients and the acute toxicity is acceptable